A detailed history of Cubist Systematic Strategies, LLC transactions in Allovir, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 19,997 shares of ALVR stock, worth $10,998. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,997
Previous 49,816 59.86%
Holding current value
$10,998
Previous $35,000 54.29%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.7 - $0.82 $20,873 - $24,451
-29,819 Reduced 59.86%
19,997 $16,000
Q2 2024

Aug 14, 2024

BUY
$0.72 - $0.82 $21,651 - $24,659
30,072 Added 152.31%
49,816 $35,000
Q1 2024

May 15, 2024

SELL
$0.64 - $0.78 $4,517 - $5,506
-7,059 Reduced 26.34%
19,744 $15,000
Q4 2023

Feb 14, 2024

BUY
$0.68 - $2.39 $9,034 - $31,753
13,286 Added 98.29%
26,803 $18,000
Q3 2023

Nov 14, 2023

BUY
$2.15 - $3.64 $1,599 - $2,708
744 Added 5.82%
13,517 $29,000
Q2 2023

Aug 14, 2023

BUY
$3.17 - $5.82 $39,073 - $71,737
12,326 Added 2757.49%
12,773 $43,000
Q1 2023

May 15, 2023

SELL
$3.94 - $7.05 $103,042 - $184,378
-26,153 Reduced 98.32%
447 $1,000
Q4 2022

Feb 14, 2023

SELL
$4.7 - $9.98 $78,024 - $165,677
-16,601 Reduced 38.43%
26,600 $136,000
Q3 2022

Nov 14, 2022

BUY
$4.13 - $8.79 $37,302 - $79,391
9,032 Added 26.43%
43,201 $341,000
Q2 2022

Aug 15, 2022

BUY
$3.26 - $7.06 $22,800 - $49,377
6,994 Added 25.74%
34,169 $133,000
Q1 2022

May 16, 2022

BUY
$6.75 - $13.52 $39,487 - $79,092
5,850 Added 27.43%
27,175 $183,000
Q4 2021

Feb 14, 2022

BUY
$12.94 - $25.99 $49,055 - $98,528
3,791 Added 21.62%
21,325 $276,000
Q3 2021

Nov 15, 2021

SELL
$16.97 - $25.06 $171,889 - $253,832
-10,129 Reduced 36.62%
17,534 $439,000
Q2 2021

Aug 16, 2021

SELL
$19.44 - $25.06 $596,088 - $768,414
-30,663 Reduced 52.57%
27,663 $546,000
Q1 2021

May 17, 2021

BUY
$20.81 - $45.5 $1.21 Million - $2.65 Million
58,326 New
58,326 $1.37 Million

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $51.2M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.